Zdrowie i gospodarka · 08/01/1999

FDA Reopens Comment Period for Non-Contraceptive Estrogen Drug Labeling Guidance

The Food and Drug Administration (FDA) is extending the comment period for its draft guidance on labeling for non-contraceptive estrogen drug products until February 13, 1999, in response to a request from industry stakeholders.